FAG
CTSO icon

Fortitude Advisory Group’s Cytosorbents Corp CTSO Stock Holding History

Fortitude Advisory Group’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,125
Closed -$13K – 1528
2021
Q4 		$13K Buy
+3,125
New +$17.5K 0.01% 959

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fortitude Advisory Group's CTSO Position: Q1 2022 in Review

Fortitude Advisory Group sold out of Cytosorbents Corp (CTSO) in Q1 2022, closing a stake of 3,125 shares — an estimated $13K sold.

Fortitude Advisory Group first reported a position in CTSO in Q4 2021 and held it in 1 quarter. The position peaked at $13K in Q4 2021. 88 funds tracked by Wall St. Rank hold CTSO as of Q1 2022.

  • Fortitude Advisory Group reported no remaining Cytosorbents Corp position as of Q1 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 3,125 Cytosorbents Corp shares in Q1 2022, an estimated $13K.
  • Fortitude Advisory Group first reported a position in Cytosorbents Corp in Q4 2021 and held it in 1 quarter.
  • Fortitude Advisory Group's Cytosorbents Corp position peaked at $13K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2022.

Based on Fortitude Advisory Group's 13F filing for Q1 2022, filed 25 May 2022.